Carnegie Capital Asset Management LLC cut its position in Clorox Co. (NYSE:CLX) by 4.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,305 shares of the company’s stock after selling 433 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Clorox were worth $1,258,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Valley National Advisers Inc. boosted its position in Clorox by 0.5% in the third quarter. Valley National Advisers Inc. now owns 849 shares of the company’s stock worth $106,000 after buying an additional 4 shares during the last quarter. Bartlett & Co. LLC boosted its position in Clorox by 13.8% in the third quarter. Bartlett & Co. LLC now owns 865 shares of the company’s stock worth $108,000 after buying an additional 105 shares during the last quarter. Van Hulzen Asset Management LLC acquired a new position in Clorox during the third quarter worth $113,000. Blue Chip Partners Inc. boosted its position in Clorox by 7.1% in the second quarter. Blue Chip Partners Inc. now owns 890 shares of the company’s stock worth $123,000 after buying an additional 59 shares during the last quarter. Finally, Catalyst Capital Advisors LLC acquired a new position in Clorox during the third quarter worth $137,000. Hedge funds and other institutional investors own 69.44% of the company’s stock.
Shares of Clorox Co. (NYSE:CLX) traded down 0.55% on Thursday, reaching $120.25. The company had a trading volume of 639,965 shares. The firm has a market capitalization of $15.48 billion, a price-to-earnings ratio of 24.20 and a beta of 0.33. The firm has a 50-day moving average price of $118.64 and a 200 day moving average price of $124.11. Clorox Co. has a 1-year low of $111.24 and a 1-year high of $140.47.
Clorox (NYSE:CLX) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $1.36 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.06. The firm had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Clorox had a return on equity of 250.82% and a net margin of 11.27%. Clorox’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $1.32 EPS. Equities research analysts predict that Clorox Co. will post $5.33 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, February 10th. Stockholders of record on Wednesday, January 25th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 2.66%. The ex-dividend date of this dividend is Monday, January 23rd. Clorox’s dividend payout ratio (DPR) is 64.26%.
A number of equities analysts have commented on the company. B. Riley reissued a “neutral” rating and set a $123.00 target price on shares of Clorox in a report on Monday, December 5th. Morgan Stanley raised Clorox from an “underweight” rating to an “equal weight” rating and set a $112.00 target price for the company in a report on Friday, December 16th. They noted that the move was a valuation call. Royal Bank Of Canada reduced their target price on Clorox from $121.00 to $115.00 and set a “sector perform” rating for the company in a report on Thursday, November 3rd. Barclays PLC raised Clorox from an “underweight” rating to an “equal weight” rating and reduced their target price for the company from $115.00 to $111.00 in a report on Monday, January 9th. Finally, Zacks Investment Research cut Clorox from a “buy” rating to a “hold” rating in a report on Tuesday, October 25th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the stock. Clorox has an average rating of “Hold” and an average target price of $126.75.
In other news, Director A D. David Mackay purchased 5,000 shares of the firm’s stock in a transaction dated Thursday, December 1st. The shares were acquired at an average price of $114.90 per share, with a total value of $574,500.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.74% of the stock is owned by insiders.
Clorox Company Profile
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co. (NYSE:CLX).